GL1X · GenesisL1 explorer

Research workbench

Human phosphdiesterase 9 substrate complex (es complex)

Analyse Human phosphdiesterase 9 substrate complex (es complex) in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
3DYL
Type
protein
Length
656 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Human phosphodiesterase 9
EC
3.1.4.35
UniProt
O76083
Ligands
PCG, IBM, MN, MG
Pockets
4 · best druggability 0.73

Structure

x-ray diffraction · 1 distinct chain · 71% helix, 0% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
A, BHuman phosphodiesterase 9 (EC 3.1.4.35)protein32871% helix, 0% strandO76083

Ligands and binding sites

  • PCG · Cyclic guanosine monophosphate · ligand · chains A
  • IBM · 3-isobutyl-1-methylxanthine · ligand · chains B
  • MN · Manganese (II) ion · metal · 2 copies · chains A, B
  • MG · Magnesium ion · metal · 2 copies · chains A, B
  • FMT · Formic acid · additive · chains B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

4 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
13770.730.8448MG, PCG
23400.720.8440MG, IBM, FMT
3720.420.8116empty
41080.380.7519empty

Interfaces

1 interface between chains.

  • A–B · 882 Ų buried · 16 hydrogen bonds · protein-protein

Compared structures

  • 3DYL · human phosphdiesterase 9 substrate complex (ES complex) · the same entry in another collection · chain A against A, TM-score 1.00
  • O76083 · AlphaFold monomer V2.0 prediction for high affinity cgmp-specific 3',5'-cyclic… · a predicted model of the same protein · chain A against A, TM-score 0.98

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.